PET radiotracers that target prostate specific membrane antigen (PSMA) such as 68Ga-PSMA are quickly becoming the standard of care when it comes to the management of biochemically recurrent PCa following definitive primary therapy. Here, FOLH1 is linked to posterior cortical atrophy.